Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy

Shibata, Shoyo; Matsushita, Maiko; Saito, Yoshimasa; Suzuki, Takeshi

doi:10.1177/2168479017751404

Cited by 11 publications

(10 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also known that QT prolongation/TdP can occur with small-molecule targeted anticancer drugs including tyrosine kinase inhibitors (e.g., nilotinib, gilteritinib, Osimertinib, and crizotinib) and proteasome inhibitors (e.g., carfilzomib) [ 21 , 27 ]. As many anticancer drugs with new mechanisms have been developed in recent years, such as antineoplastic monoclonal antibodies and protein kinase inhibitors, there has been an increase in their use [ 28 ]; this may be an explanation for the number of patients who experienced QT prolongation/TdP who were also being treated with anticancer drugs.…”

Section: Discussionmentioning

confidence: 99%

Drug-Induced QT Prolongation and Torsade de Pointes in Spontaneous Adverse Event Reporting: A Retrospective Analysis Using the Japanese Adverse Drug Event Report Database (2004–2021)

Uchikawa

Hashiguchi

Shiga

2022

Drugs - Real World Outcomes

View full text Add to dashboard Cite

Background Drugs with new mechanisms of action are continually being developed, but it is difficult to capture whether a drug induces QT prolongation/torsade de pointes (TdP) in preclinical and preapproval clinical trials. Objective To evaluate drugs associated with drug-induced QT prolongation/TdP using a real-world database in Japan. Patients and methods A search was performed in the Japanese Adverse Drug Event Report (JADER) database for QT prolongation and TdP. The reporting odds ratio (ROR) was calculated to identify potential drug-induced QT prolongation/TdP association. Results Among the reported 4,326,484 data entries, 3410 patients exhibited QT prolongation/TdP (2707 with QT prolongation, 703 with TdP) with the suspected drugs. Of these patients, 53.9% were females. The highest occurrence was in the 70-to 79-year-old age group (24.7%). The most common types of drugs involved were cardiovascular drugs, central nervous system (CNS) drugs, anticancer drugs, and anti-infective drugs; the rate of overdose was reportedly very low at 1.6%. The highest adjusted RORs were observed for nifekalant (351.41, 95% confidence interval (CI) 235.85-523.59),

show abstract

Section: Discussionmentioning

confidence: 99%

Drug-Induced QT Prolongation and Torsade de Pointes in Spontaneous Adverse Event Reporting: A Retrospective Analysis Using the Japanese Adverse Drug Event Report Database (2004–2021)

Uchikawa

Hashiguchi

Shiga

2022

Drugs - Real World Outcomes

View full text Add to dashboard Cite

show abstract

“…19 This is expected to encourage increased R&D by Japanese pharmaceutical companies, especially in therapeutic areas where contributions have been made mainly by global pharmaceutical companies, resulting in the Japanese pharmaceutical market becoming more comparable to the global market. Actually, several reports have showed an upward R&D trend, especially in oncologic drugs in Japan, [25][26][27][28][29][30] which is being accelerated through these schemes.…”

Section: Discussionmentioning

confidence: 99%

Analysis of new molecular entity trends from 2006 to 2015 in Japan

Shibata

Fukumoto

Ozaki

et al. 2020

Journal of Generic Medicines

Self Cite

View full text Add to dashboard Cite

Japan is one of the largest pharmaceutical markets in the world, and as such, pharmaceutical companies are intensively conducting research and development of new drugs in Japan. However, information on Japanese pharmaceutical market profiles is limited. In this context, we elucidated the market characteristics and trends of new molecular entities approved between 2006 and 2015 in Japan. Among antineoplastic and immunomodulating agents, the highest number was first approved in the United States, and for nervous system drugs, the highest number was first approved in Europe. The alimentary tract and metabolism and the musculoskeletal system were the therapeutic areas for which the most drugs were approved for the first time in Japan. Most of the musculoskeletal system drugs were developed by Japanese companies, and most of the antineoplastic and immunomodulating agents were developed outside of Japan. Using various performance indexes, such as market forecasts and significance of clinical benefits, we determined that the number of new molecular entities and market size increased and the number of drugs with significant clinical benefits decreased. These results suggest that new molecular entity innovation by Japanese companies has been decreasing and the government’s comparative method for pricing does not work well in Japan.

show abstract

“…Top 30 selling anticancer drugs in Japan. Year 2010 2011 2012 2013 2014 2015 2016 L01A 1 1 1 1 1 1 1 L01B 6 6 5 6 5 5 5 L01C 3 3 3 3 1 1 1 L01F 1 1 1 1 1 1 1 L01G 5 6 5 5 6 6 8 L01H 5 6 7 6 8 8 8 L01X 1 1 1 1 1 1 1 L02A 4 4 4 4 3 3 3 L02B 4 2 3 3 4 4 2 Source: Modified from Shibata et al 11 been a mainstream of cancer therapy. The number of anti-cancer drugs available each year in Japan during this period is shown in Table 4.…”

Section: Yearmentioning

confidence: 99%

“…Prescription volume by ATC category. Source: Modified from Shibata et al 11 (The maximum y-axis values are (a) 250,000,000, (b) 50,000,000, and (c) 6,000,000.) 0 50,00,00,00,000…”

Section: Atc Codementioning

confidence: 99%

Japan oncology market overview: Current and future perspectives

Shibata

Matsushita

Suzuki

et al. 2019

Journal of Generic Medicines

Self Cite

View full text Add to dashboard Cite

The anti-cancer drug market is considered a growth market in Japan and across the world. Pharmaceutical companies have made every effort to deliver innovative drugs in this field, boosting market growth. In their research and development of anti-cancer drugs, these pharmaceuticals need to identify the optimal drug modalities in order to maximize profit, as the drugs are divided into two groups: cytotoxic-based drugs and target-based drugs. Although there have been numerous studies focused on the critical role of molecular target cancer therapy in anti-cancer drug development in Japan and elsewhere, few studies have quantitatively assessed the Japanese market using actual prescription data. This article provides an overview of the anti-cancer drug market in Japan as a foundation for formulating a global business strategy. It identifies key characteristics of the Japanese anti-cancer drug market and offers a prognosis of the market based on study findings.

show abstract

Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy

Abstract: The availability and increasing use of innovative but more expensive targeted therapies were major drivers of increases in pharmaceutical expenditures for cancer treatment in Japan. Therefore, the effective use of genetic testing can mitigate these rising costs.

Cited by 11 publications

References 28 publications

Drug-Induced QT Prolongation and Torsade de Pointes in Spontaneous Adverse Event Reporting: A Retrospective Analysis Using the Japanese Adverse Drug Event Report Database (2004–2021)

Drug-Induced QT Prolongation and Torsade de Pointes in Spontaneous Adverse Event Reporting: A Retrospective Analysis Using the Japanese Adverse Drug Event Report Database (2004–2021)

Analysis of new molecular entity trends from 2006 to 2015 in Japan

Japan oncology market overview: Current and future perspectives

Contact Info

Product

Resources

About